This trial will test whether an MRI can predict how well a patient will respond to radiation therapy and androgen deprivation therapy for high-risk, localized prostate cancer.
- Prostate Cancer
1 Primary · 1 Secondary · Reporting Duration: within 18 months of RT completion
Awards & Highlights
1 Treatment Group
1 of 1
100 Total Participants · 1 Treatment Group
Primary Treatment: Restriction Spectrum Imaging Magnetic Resonance Imaging · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Male Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment for this trial still open?
"This medical experiment, which was initially uploaded to clinicaltrials.gov on December 29th 2020 and updated as recently as May 16th 2022, is currently recruiting participants." - Anonymous Online Contributor
What is the total population size participating in this investigation?
"Affirmative. According to data hosted on clinicaltrials.gov, this medical experiment is currently enrolling patients. Initially posted in December 2020 and last edited in May 2022, the study seeks 100 participants across a single site." - Anonymous Online Contributor
Is Restriction Spectrum Imaging Magnetic Resonance Imaging a reliable diagnostic tool for patients?
"Our internal assessment of Restriction Spectrum Imaging Magnetic Resonance Imaging's safety resulted in a score of 2, as the technology has not yet been evaluated for efficacy but does possess some evidence regarding its safety." - Anonymous Online Contributor